Viral Safety Gaps in Biotech Submissions: What the Data Reveals

A Signal the Market Is Already Acting On

German hospital procurement notices for pharmaceutical products, including blood products, with supply arrangements commencing on 1 January 2026 and, in one case, 1 July 2026, are more than logistical events. They create commercially critical supply windows. For suppliers of cell-line-derived biologics, the ability to manufacture and supply a product lawfully and reliably depends, among other factors, on the applicable manufacturing authorisation, GMP compliance status, and the adequacy of the quality and viral-safety evidence supporting the authorised manufacturing process. A regulatory or GMP issue does not automatically lead to exclusion from a procurement procedure. However, where it affects eligibility, supply capability, contractual performance, or the timely implementation of a required post-authorisation change, it can create a direct and quantifiable commercial risk.

Viral-safety evaluation is one area that may require particular attention. ICH Q5A(R2), finally adopted by CHMP on 14 December 2023 and effective from 14 June 2024, substantially updates the earlier Q5A framework, first adopted in 1997. Section 7 introduces specific viral-safety considerations for continuous manufacturing, including considerations arising from extended cell-culture duration and other process-specific features. The revised guideline also includes updated considerations for the statistical evaluation of viral-clearance data. Where a manufacturer develops, changes, or justifies a manufacturing process — particularly when introducing continuous manufacturing — it should assess whether the available viral-safety evidence remains appropriate for the product, process, and proposed regulatory change. Any identified gap may become relevant during a variation procedure or another regulatory assessment of the underlying quality evidence.

Continuous Manufacturing and the Q5A(R2) Frontier

Unlike conventional batch manufacturing, continuous manufacturing may involve extended production culture and a process configuration in which material flows through connected unit operations over time. ICH Q5A(R2) identifies longer periods in production culture as a consideration that should be addressed in the viral-safety strategy for a continuous process. The appropriateness of an existing viral-clearance package must therefore be assessed in light of the specific manufacturing configuration, including the cell-culture duration, process design, sampling strategy, potential diversion or segregation arrangements, and the integration of downstream unit operations.

A viral-safety package developed for a conventional batch process may not automatically address all considerations relevant to a continuous process. Where a manufacturer introduces continuous manufacturing or makes another process change with potential implications for viral safety, the available evidence should be evaluated against the changed process and the current expectations in ICH Q5A(R2). This assessment can be performed before a variation is submitted and can help identify questions, evidence gaps or additional work that may need to be addressed as part of the regulatory strategy. The outcome will depend on the product, process, proposed change and supporting data.

Vestango combines public regulatory intelligence with structured regulatory review to help clients prioritise such assessments. Its monitoring workflow draws on regulatory sources that may include EudraGMDP records, publicly available EMA medicine documents and assessment reports, CTIS information, and relevant legacy EudraCT records. Public information can support the identification of externally observable regulatory, manufacturing and clinical-development signals; confirmation of product-specific viral-safety gaps requires review of the relevant manufacturing and dossier documentation.

The resulting assessment can be presented as a structured and queryable profile, linking identified questions or evidence gaps to the relevant sections of ICH Q5A(R2), the available supporting sources and the potential regulatory actions for further evaluation. This is not a substitute for a product-specific scientific and regulatory assessment, but it can provide a transparent basis for prioritising due diligence, variation-readiness or remediation work.

Nitrosamine Risk Assessment: A Converging Compliance Surface

Alongside developments in viral-safety evaluation, nitrosamine risk assessment remains an important area of regulatory monitoring for medicinal-product manufacturers. Nitrosamine impurities may arise in relation to active substances, excipients, reagents, solvents, manufacturing processes, packaging materials or cross-contamination, depending on the specific product and manufacturing process. For biologics, relevance should therefore be assessed case by case, based on the materials used, process conditions and potential sources of nitrosamine formation or introduction.

EMA guidance on nitrosamine impurities continues to evolve as scientific knowledge, analytical capability and understanding of compound-specific carcinogenic potency develop. Current regulatory approaches to setting acceptable intakes may use several lines of evidence, including compound-specific data, read-across approaches and, where robust carcinogenicity data are available, benchmark-dose modelling. Published work comparing TD50- and benchmark-dose-based approaches, including analyses involving N-nitrosotrimetazidine, illustrates the potential impact that methodological choices can have on the characterisation of carcinogenic potency and the derivation of acceptable intake limits.

A scientific publication or methodological development does not, by itself, create an immediate regulatory obligation for every marketing-authorisation holder. However, manufacturers may wish to monitor developments that could affect the scientific basis of a compound-specific nitrosamine assessment, the applicable acceptable intake, analytical testing strategy or regulatory justification. Where a regulatory authority revises a limit, methodology or expectation relevant to a specific nitrosamine, the need for further risk assessment, confirmatory testing or a regulatory update will depend on the compound, the exposure level, the product and the applicable regulatory guidance.

Pharmacovigilance Continuity Across the Quality-Safety Interface

Viral-safety evaluation and cell-substrate characterisation are principally quality and CMC matters, typically documented in Module 3 of the electronic Common Technical Document (eCTD). Their potential implications may nevertheless extend beyond the quality dossier where new information affects, or may affect, the safety of patients, the benefit–risk balance of the product, product information, risk-minimisation measures or other pharmacovigilance activities. The relevance of any CMC finding for pharmacovigilance should therefore be assessed according to its nature, evidence base and potential clinical significance.

Under the EU pharmacovigilance framework, the marketing-authorisation holder is required to maintain a pharmacovigilance system, and the qualified person responsible for pharmacovigilance (QPPV) must have oversight of the safety profile of authorised medicines and emerging safety concerns. PSURs, prepared in the EU format aligned with ICH PBRER principles, support periodic evaluation of the product’s benefit–risk balance. A change to viral-clearance evidence or cell-substrate documentation does not automatically require inclusion in a PSUR/PBRER or initiation of a GVP Module IX signal-management process. Such action may be relevant where the change identifies, confirms or materially alters a potential safety concern, or otherwise affects the product’s benefit–risk assessment.

Effective lifecycle management therefore requires appropriate communication between CMC, quality, regulatory affairs and pharmacovigilance functions. Before submitting a CMC variation, the marketing-authorisation holder should consider whether the proposed change or the evidence supporting it has implications for the pharmacovigilance system, reference safety information, risk-management activities or the next scheduled benefit–risk evaluation. The scope of that assessment should be proportionate to the potential impact on patient safety and the available evidence.

Vestango can support this cross-functional review by organising relevant public regulatory information, including publicly available adverse-reaction reporting patterns, EudraGMDP records and EMA medicine documents or published assessment reports. These sources can help identify externally observable signals or questions for further assessment. They cannot, on their own, establish the complete status of a manufacturer’s pharmacovigilance system or quality dossier; confirmation requires product-specific review of the relevant documentation and internal safety information.

The In-Licensing Dimension

For biologic assets considered in an in-licensing transaction, the viral-safety evidence may be a relevant element of regulatory due diligence. This is particularly the case where the asset is expected to undergo a manufacturing-process change, a scale-up, a technology transfer, a change of manufacturing site, an extension of the marketing authorisation, or another post-authorisation activity that could require reassessment of the available quality data. The relevance and scale of this risk depend on the product, the manufacturing process, the development stage, the regulatory route and the evidence available to support the proposed change.

A viral-clearance package developed under the earlier Q5A(R1) framework is not, by itself, evidence of a compliance deficiency. However, where a transaction involves a planned process change or regulatory activity, the parties should assess whether the available viral-safety evidence remains appropriate in light of ICH Q5A(R2), the current manufacturing configuration and the intended post-transaction strategy. If additional data, justification or regulatory interaction is required, this may affect the timing, scope and cost of post-acquisition development or lifecycle-management activities. These considerations may therefore be relevant to due-diligence findings, transaction planning and, where appropriate, commercial assumptions in the term sheet.

Vestango can support an initial, structured review of publicly available regulatory information and the documentation made available by the client. The review can identify externally observable regulatory signals, clarify the questions that require dossier-level verification, and map product-specific issues to the relevant provisions of ICH Q5A(R2). The scope, timing and depth of the review should be agreed in advance and will depend on the availability and completeness of the underlying information.

Where a biologic asset has a viral-safety package developed before ICH Q5A(R2) became effective on 14 June 2024, Vestango can support a product-specific Q5A(R2) readiness assessment. This may combine dossier review with relevant public information, such as EudraGMDP records, EMA medicine information and publicly available adverse-reaction reporting data. Public sources can help validate factual regulatory information and identify questions for further assessment; they do not replace access to the relevant quality dossier, pharmacovigilance documentation or internal product data. Contact Vestango.

The analysis in this article draws on publicly available regulatory data, published guidelines, and the accumulated experience of Vestango Life Sciences in EU and Polish regulatory affairs. It reflects patterns we observe — not universal conclusions. Every regulatory situation is product-specific, market-specific, and jurisdiction-specific. What applies to one portfolio may not apply to yours. If any of the issues raised here resonate with your situation, the right next step is a structured, case-specific conversation — not the application of general conclusions. With our founder Paweł Wojtaszczyk, Ph.D. Eng., we work at the intersection of data science and regulatory affairs, translating that combination into real market implementations. We solve problems and build companies operating in the life sciences market. Contact Vestango.